SEARCH

SEARCH BY CITATION

References

  • 1
    Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351: 9981012.
  • 2
    Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 363548.
  • 3
    Finck SJ, Giuliano AE, Morton DL. LDH and melanoma. Cancer 1983; 51: 8403.
  • 4
    Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 1995; 31A: 1898902.
  • 5
    von Schoultz E, Hansson LO, Djureen E, Hansson J, Karnell R, Nilsson B, Stigbrand T, Ringborg U. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res 1996; 6: 1337.
  • 6
    Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R. Biomarkers in melanoma. Ann Oncol 2009; 20( Suppl 6): vi8vi13.
  • 7
    Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 61525.
  • 8
    Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004; 4: 1.
  • 9
    Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, Lehvaslaiho M, Carninci P, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA 2008; 105: 204227.
  • 10
    Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T, Chen YT, Chua R, Gurung S, Gnjatic S, Jungbluth AA, Caballero OL, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 2009; 37: D816D819.
  • 11
    Stevenson BJ, Iseli C, Panji S, Zahn-Zabal M, Hide W, Old LJ, Simpson AJ, Jongeneel CV. Rapid evolution of cancer/testis genes on the X chromosome. BMC Genomics 2007; 8: 129.
  • 12
    van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 16437.
  • 13
    Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M, Schneider C. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 2006; 103: 111605.
  • 14
    Liu W, Cheng S, Asa SL, Ezzat S. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res 2008; 68: 810412.
  • 15
    Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995; 63: 37580.
  • 16
    Old LJ. Cancer vaccines: an overview. Cancer Immun 2008; 8( Suppl 1): 1.
  • 17
    Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G, Coulie PG. Functions of anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res 2008; 68: 393140.
  • 18
    Fontana R, Bregni M, Cipponi A, Raccosta L, Rainelli C, Maggioni D, Lunghi F, Ciceri F, Mukenge S, Doglioni C, Colau D, Coulie PG, et al. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood 2009; 113: 165160.
  • 19
    Nicholaou T, Ebert L, Davis ID, Robson N, Klein O, Maraskovsky E, Chen W, Cebon J. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol 2006; 84: 30317.
    Direct Link:
  • 20
    Scanlan MJ, Gordon CM, Williamson B, Lee SY, Chen YT, Stockert E, Jungbluth A, Ritter G, Jager D, Jager E, Knuth A, Old LJ. Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer 2002; 98: 48592.
  • 21
    Chen ME, Lin SH, Chung LW, Sikes RA. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem 1998; 273: 1761825.
  • 22
    Brinkmann U, Vasmatzis G, Lee B, Yerushalmi N, Essand M, Pastan I. PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus. Proc Natl Acad Sci USA 1998; 95: 1075762.
  • 23
    Zendman AJ, Van Kraats AA, Weidle UH, Ruiter DJ, Van Muijen GN. The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and ewing's sarcoma. Int J Cancer 2002; 99: 3619.
  • 24
    Brinkmann U, Vasmatzis G, Lee B, Pastan I. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res 1999; 59: 14458.
  • 25
    Cilensek ZM, Yehiely F, Kular RK, Deiss LP. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther 2002; 1: 3807.
  • 26
    Iwamoto O, Nagao Y, Shichijo S, Eura M, Kameyama T, Itoh K. Detection of MAGE-4 protein in sera of patients with head-and-neck squamous-cell carcinoma. Int J Cancer 1997; 70: 28790.
  • 27
    Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188: 2232.
  • 28
    Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, Jungbluth AA, Ritter G, Jager D, Jager E, Knuth A, Old LJ. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002; 62: 40417.
  • 29
    Qin QP, Christiansen M, Pettersson K. Point-of-care time-resolved immunofluorometric assay for human pregnancy-associated plasma protein A: use in first-trimester screening for down syndrome. Clin Chem 2002; 48: 47383.
  • 30
    von Lode P, Rosenberg J, Pettersson K, Takalo H. A europium chelate for quantitative point-of-care immunoassays using direct surface measurement. Anal Chem 2003; 75: 3193201.
  • 31
    Eskelin S, Pyrhönen S, Hahka-Kemppinen M, Tuomaala S, Kivelä T. A prognostic model and staging for metastatic uveal melanoma. Cancer 2003; 97: 46575.
  • 32
    Vihinen P, Pyrhönen S. Long-term response to daily low-dose subcutaneous interferon-alpha2b in a patient with pretreated metatstatic uveal melanoma in the liver and lung. Case Rep Oncol 2008; 1: 510.
  • 33
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 20516.
  • 34
    Vihinen PP, Hernberg M, Vuoristo MS, Tyynela K, Laukka M, Lundin J, Ivaska J, Pyrhonen S. A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res 2010; 20: 31825.
  • 35
    Mirtti T, Nylund C, Lehtonen J, Hiekkanen H, Nissinen L, Kallajoki M, Alanen K, Gullberg D, Heino J. Regulation of prostate cell collagen receptors by malignant transformation. Int J Cancer 2006; 118: 88998.
  • 36
    Boguski MS, Lowe TM, Tolstoshev CM. dbEST—database for “expressed sequence tags”. Nat Genet 1993; 4: 3323.
  • 37
    Nelson PS, Pritchard C, Abbott D, Clegg N. The human (PEDB) and mouse (mPEDB) prostate expression databases. Nucleic Acids Res 2002; 30: 21820.
  • 38
    Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004; 37: 5128.
  • 39
    Stoitchkov K, Letellier S, Garnier JP, Bousquet B, Tsankov N, Morel P, Ghanem G, Le Bricon T. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B. Melanoma Res 2002; 12: 25562.
  • 40
    Kelley MC, Gupta RK, Hsueh EC, Yee R, Stern S, Morton DL. Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. J Clin Oncol 2001; 19: 117682.
  • 41
    Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 2006; 106: 11309.
  • 42
    Palmieri G, Ascierto PA, Perrone F, Satriano SM, Ottaiano A, Daponte A, Napolitano M, Caraco C, Mozzillo N, Melucci MT, Cossu A, Tanda F, et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol 2003; 21: 76773.
  • 43
    Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 473845.
  • 44
    Bosserhoff AK. Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression. Pigment Cell Res 2005; 18: 4116.
  • 45
    Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57: 314953.
  • 46
    Garnier JP, Letellier S, Cassinat B, Lebbe C, Kerob D, Baccard M, Morel P, Basset-Seguin N, Dubertret L, Bousquet B, Stoitchkov K, Le Bricon T. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer 2007; 43: 81621.
  • 47
    Lin J, Blake M, Tang C, Zimmer D, Rustandi RR, Weber DJ, Carrier F. Inhibition of p53 transcriptional activity by the S100B calcium-binding protein. J Biol Chem 2001; 276: 3503741.
  • 48
    Markowitz J, MacKerell AD Jr, Weber DJ. A search for inhibitors of S100B, a member of the S100 family of calcium-binding proteins. Mini Rev Med Chem 2007; 7: 60916.
  • 49
    Andres R, Mayordomo JI, Visus C, Isla D, Godino J, Escudero P, Saenz A, Ortega E, Lastra R, Lambea J, Aguirre E, Elosegui L, et al. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma. Am J Clin Oncol 2008; 31: 3359.
  • 50
    Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999; 56: 33844.
  • 51
    Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer 2008; 123: 23706.